Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Sargent

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2009
Early stopping for benefit in National Cancer Institute-sponsored randomized Phase III trials: the system is workingDaniel Sargent
JAMA Oncology|July 17, 2015
Improved Outcomes in Metastatic Colon Cancer: Giving Credit Where Credit Is DueDaniel Sargent
Oncology (Williston Park, N.Y.)|June 16, 2006
General and statistical hierarchy of appropriate biologic endpointsDaniel Sargent
Clinical Advances in Hematology & Oncology : H&O|June 13, 2009
Importance of randomization in early clinical trialsDaniel Sargent
Gastrointestinal Cancer Research : GCR|April 4, 2009
Genomic classifiers in colon cancer - clinical utilityDaniel Sargent
The Oncologist|March 19, 2010
What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?Daniel Sargent
Seminars in Oncology|June 14, 2002
Issues in clinical trial design for tumor marker studiesDaniel Sargent, Carmen Allegra
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first lineAxel Grothey, Daniel Sargent
The Oncologist|June 24, 2006
End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?Sharlene Gill, Daniel Sargent
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Molecular diagnostics: assays, tissues, progress, and pitfallsCarmen Allegra, Daniel Sargent
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2009
Early stopping for benefit in National Cancer Institute-sponsored randomized Phase III trials: the system is workingDaniel Sargent
JAMA Oncology|July 17, 2015
Improved Outcomes in Metastatic Colon Cancer: Giving Credit Where Credit Is DueDaniel Sargent
Oncology (Williston Park, N.Y.)|June 16, 2006
General and statistical hierarchy of appropriate biologic endpointsDaniel Sargent
Clinical Advances in Hematology & Oncology : H&O|June 13, 2009
Importance of randomization in early clinical trialsDaniel Sargent
Gastrointestinal Cancer Research : GCR|April 4, 2009
Genomic classifiers in colon cancer - clinical utilityDaniel Sargent
The Oncologist|March 19, 2010
What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?Daniel Sargent
Seminars in Oncology|June 14, 2002
Issues in clinical trial design for tumor marker studiesDaniel Sargent, Carmen Allegra
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first lineAxel Grothey, Daniel Sargent
The Oncologist|June 24, 2006
End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?Sharlene Gill, Daniel Sargent
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Molecular diagnostics: assays, tissues, progress, and pitfallsCarmen Allegra, Daniel Sargent
Pageof 5